Kukoamine A and B Antagonize LPS for Sepsis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis and autoimmune diseases are ineffective and often cause adverse reactions, with a lack of reliable drugs due to the complexity of the immune response and unclear mechanisms of traditional Chinese medicine constituents.
Innovation Solution
The use of Kukoamine A and Kukoamine B, extracted from Lycii cortex, to antagonize bacterial endotoxin/lipopolysaccharide (LPS) and unmethylated DNA, key factors inducing sepsis and autoimmune disease, through a biosensor screening and directional separation platform.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional Chinese medicine extracts are used to treat sepsis and autoimmune diseases, then therapeutic effects are observed, but the material basis and mechanisms are unclear
Solution Approach 1:
The patent extracts specific active constituents (kukoamine A and kukoamine B) from the traditional Chinese medicine Lycii cortex using chromatographic separation techniques. This extraction process isolates the effective components while removing inactive or potentially harmful substances, thereby providing clear material basis for the therapeutic effects observed with traditional Chinese medicine extracts.
2Ease of manufacture
If empirical non-specific anti-inflammatory agents are used, then treatment is available, but survival rates are not improved and serious adverse reactions occur
Solution Approach 1:
The patent isolates specific active constituents (kukoamine A and kukoamine B) from Lycii cortex through chromatographic separation, extracting only the beneficial anti-inflammatory components while eliminating inactive or harmful substances present in the whole extract, thereby reducing adverse reactions while maintaining therapeutic availability.
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic effect on specific molecular targets (LPS and CpG DNA) rather than providing broad non-specific anti-inflammatory action. This targeted approach allows the drug to act precisely where needed, improving efficacy while reducing off-target adverse effects associated with empirical anti-inflammatory agents.
3Difficulty of detecting and measuring
If key molecules in immune response are inhibited, then immediate cause of organ injury is targeted, but curative effect is difficult to achieve and immune system disorder may be aggravated
Solution Approach 1:
Instead of inhibiting immune response molecules as conventional approaches do, the patent uses kukoamine A and B to antagonize pathogen-associated molecular patterns (LPS and CpG DNA) at their source. This inverted approach blocks the initiation of the harmful immune response rather than suppressing downstream effects, thereby achieving curative effect without aggravating immune system disorder.
Solution Approach 2:
The patent applies preliminary action by blocking the interaction between pathogen-associated molecular patterns (LPS and CpG DNA) and immune cells before the harmful immune response cascade is fully activated. This early intervention prevents the formation of immune complexes and subsequent organ injury, achieving better curative effect than late-stage inhibition of immune molecules.
4Reliability
If LPS and CpG DNA are blocked, then sepsis and autoimmune disease are prevented from the source, but specific curative drugs are needed which have been lacking
Solution Approach 1:
The patent extracts and isolates the specific curative constituents (kukoamine A and kukoamine B) from Lycii cortex using systematic chromatographic separation methods. This extraction process provides well-defined chemical entities with known structures and mechanisms, transforming the vague traditional Chinese medicine extract into a precise pharmaceutical agent that can be reliably manufactured and regulated.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Kukoamine A and B demonstrate high affinity for LPS and CpG DNA, neutralizing their effects, inhibiting inflammatory mediator release, and improving survival rates in animal models, providing a safe and effective treatment for sepsis and autoimmune diseases.
Implementation Method 1
Kukoamine A and B demonstrate high affinity for LPS and CpG DNA, neutralizing their effects
Data Source
AI summary
The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.